WO2017169966A1 - Bifidobacterium présentant une capacité de promotion de la sécrétion de la sérotonine - Google Patents

Bifidobacterium présentant une capacité de promotion de la sécrétion de la sérotonine Download PDF

Info

Publication number
WO2017169966A1
WO2017169966A1 PCT/JP2017/011154 JP2017011154W WO2017169966A1 WO 2017169966 A1 WO2017169966 A1 WO 2017169966A1 JP 2017011154 W JP2017011154 W JP 2017011154W WO 2017169966 A1 WO2017169966 A1 WO 2017169966A1
Authority
WO
WIPO (PCT)
Prior art keywords
bifidobacteria
bifidobacterium
serotonin
strain
present
Prior art date
Application number
PCT/JP2017/011154
Other languages
English (en)
Japanese (ja)
Inventor
恭久 長▲崎▼
篤史 大木
洋介 砂田
Original Assignee
日清食品ホールディングス株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日清食品ホールディングス株式会社 filed Critical 日清食品ホールディングス株式会社
Publication of WO2017169966A1 publication Critical patent/WO2017169966A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor

Definitions

  • the present invention relates to a strain of bifidobacteria derived from infant intestine having high ability to promote serotonin secretion, a beverage containing the treated product of the bifidobacteria, and a food.
  • Non-patent Document 1 brain-derived neural factor BDNF in the hippocampus and frontal lobe (Brain derived The neurotrophic factor) concentration is increased, and antidepressant action is obtained.
  • BA butyric acid
  • serotonin is essential for the biosynthesis of BDNF (Non-patent Document 2).
  • An object of the present invention is to provide a strain of bifidobacteria of infant intestinal origin having high ability to promote serotonin secretion and a food and drink containing the treated product of the bifidobacteria.
  • the present inventors focused on the fact that serotonin is essential for the biosynthesis of BDNF, and as a result of screening a large number of bifidobacteria, they found that there is a bifidobacteria having a high ability to promote serotonin secretion. We came to complete the invention.
  • the first invention of the present application is a bifidobacteria belonging to the genus Bifidobacterium having the ability to promote serotonin secretion
  • the Bifidobacterium described in the first invention of the present application is a bifidobacteria. It is a longum N61 strain (NITE BP-02214).
  • the applicant of the present application also intends a food or drink containing the bifidobacteria, or a serotonin secretion promoter containing the bifidobacteria as an active ingredient. That is, the third invention of the present application is a food and drink containing the bifidobacteria described in the second invention of the present application, and the fourth invention of the present application is a serotonin secretion containing the bifidobacteria described in the second invention as an active ingredient It is an accelerator.
  • the bifidobacteria of the present invention have a serotonin secretion promoting ability.
  • FIG. 1 is a diagram comparing the serotonin secretion promoting ability of the strain of the present invention and a comparative strain.
  • FIG. 2 is a diagram comparing the skimmed milk medium growth properties of the strain of the present invention and the comparative strain.
  • Bifidobacterium longum N61 strain (NITE BP-02214)
  • the Bifidobacterium of the present invention is Bifidobacterium longum.
  • Bifidobacteria belonging to Bifidobacterium longum it is Bifidobacterium longum N61 strain (NITE BP-02214).
  • the symbol N61 referred to in the present invention is a number uniquely assigned to the strain by Nisshin Foods Holdings Co., Ltd., and this Bifidobacterium longum N61 strain is isolated for the first time by the present inventor.
  • the Bifidobacterium longum N61 strain of the present invention has been deposited under the following conditions.
  • the mycological properties of Bifidobacterium longum N61 strain of the invention of Japan are as follows: As shown in Tables 1 and 2 of This bacteriological property is according to the method described in Bergey's manual of systematic bacteriology Vol.
  • Table 1 shows the shape and the like of this strain
  • Table 2 shows the results of testing the sugar utilization by Api 50 CH and Api CHL (manufactured by BioMérieux).
  • "+” indicates fermentability and "-” indicates non-fermentability.
  • the Bifidobacterium longum N61 strain of the present invention has a high ability to promote serotonin secretion as shown in the following experimental example.
  • the confirmation of the ability to promote serotonin secretion was carried out by the following test method.
  • the subject (culture fluid) used for evaluation of serotonin secretion promoting ability was obtained by culturing bifidobacteria in GAM medium (GAM Broth "Nissui") shown in Table 3 at 37 ° C for 24 hours.
  • RIN14B cells which are enterochromaffin-like cells derived from rat pancreatic cancer, were used as cells.
  • RIN14B cells cultured in a petri dish are detached using Accutase (Innova Cell Technologies) (incubate at 37 ° C for 10 minutes), and then 500 ⁇ l of 2 ⁇ 10 5 cells / ml of RIN14B cells are seeded on a 24-well plate. Incubate at 37 ° C., 5% CO 2 for 1 hour. The cell counter Countess (invitrogen) was used for cell count.
  • the above-obtained subject (bifidobacteria culture solution) is adjusted to a constant value of turbidity Optical Density (OD), diluted 20-fold with RIN14B cell culture medium, and RIN14B cell seeded and incubated wells It was added to a final concentration of 10% Te, 37 ° C., and cultured for 24 hours under 5% CO 2. After culture, the culture supernatant of RIN14B cells to which the subject was added was collected, and the serotonin content in the supernatant was measured with a commercially available serotonin immunoassay kit (Enzo).
  • Enzo serotonin immunoassay kit
  • the preculture liquid was inoculated into a 10% SM (skimmed milk) medium, and this was cultured at 37 ° C. for 24 hours, and the growth in milk medium was evaluated by the number of bifidobacteria.
  • the bifidobacteria of the present invention can be used by being contained in food and beverage.
  • the Bifidobacterium of the present invention can be suitably used particularly for dairy products, but, for example, fermented milk containing bifidobacteria and a lactic acid bacteria beverage containing bifidobacteria can be considered.
  • fermented milk with non-fat milk solid content of 8.0% or more
  • lactic acid bacteria beverage non-fat milk
  • 1.0 ⁇ 10 6 cfu / ml or more is preferable if it is a lactic acid bacteria beverage (less than non-fat milk solid content of 3.0%)
  • the above-mentioned number of bacteria can be realized by growing them in a fermentation broth or growing them in the form of a final product.
  • fermented milk containing bifidobacteria and lactic acid bacteria containing bifidobacteria it can be used for dairy products such as butter, processed eggs such as mayonnaise, and confectionery breads such as butter cake. In addition, it can be suitably used for processed foods such as instant noodles and cookies.
  • the food of the present invention may be formulated (for example, powder, granules, capsules, tablets, etc.) together with the above-mentioned Bifidobacterium, if necessary, with addition of suitable carriers and additives. Good.
  • the bifidobacteria of the present invention is also useful to be contained in food for specified health use, dietary supplements and the like in addition to general beverages and foods.
  • the bifidobacteria of the present invention is used in the cosmetic field such as lotions and the like, the pharmaceutical field such as intestinal conditioners, the daily use field such as tooth powder, silage, animal feed, and animal feed and plant fertilizers such as plant liquid fertilizers. Is also applicable.
  • the bifidobacteria of the present invention (Bifidobacterium longum strain N61) has a high ability to promote serotonin secretion.
  • the serotonin secretion promoting ability was evaluated by the following procedure.
  • Each of the strain of the present invention and the comparative strain was cultured at 37 ° C. for 24 hours in GAM medium (GAM Broth “Nissui”) shown in Table 3 to obtain a subject (culture fluid).
  • RIN14B cells cultured in a petri dish are detached using Accutase (Innova Cell Technologies) (incubate at 37 ° C for 10 minutes), and then 500 ⁇ l of 2 ⁇ 10 5 cells / ml of RIN14B cells are seeded on a 24-well plate. Incubated at 37 ° C., 5% CO 2 for 1 hour. The cell counter Countess (invitrogen) was used for cell count.
  • the above-obtained subject (Bifidobacterium culture fluid) is adjusted to a constant value of turbidity Optical Density (OD), diluted 20-fold with RIN14B cell culture medium, and then added to wells after RIN14B cell seeding incubation It was added to a final concentration of 10% and cultured at 37 ° C., 5% CO 2 for 24 hours. After culture, the culture supernatant of RIN14B cells to which the subject was added was collected, and the serotonin content in the supernatant was measured with a commercially available serotonin immunoassay kit (Enzo).
  • Enzo serotonin immunoassay kit
  • the cells were inoculated into a 10% SM (skimmed milk) medium, cultured at 37 ° C. for 24 hours, and the growth of the skimmed milk medium was evaluated by the number of bifidobacteria.
  • SM saturated milk
  • the bacterial count of the strain of the present invention (Bifidobacterium longum N61 strain) is 2.1 ⁇ 10 8 cfu / ml, which is a level at which there is no problem in producing bifidobacteria-containing fermented milk and bifidobacteria-containing lactic acid bacteria beverage.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Le problème à résoudre par la présente invention consiste à préparer une souche de bifidobactéries présentant une capacité élevée de promotion de la sécrétion de la sérotonine, et un aliment et/ou une boisson contenant une forme traitée du Bifidobacterium. Les inventeurs ont mis l'accent sur le fait que la sérotonine est indispensable à la biosynthèse du BDNF et, en résultat au criblage de nombreuses bifidobactéries, ont découvert un Bifidobacterium dérivé de l'intestin du nourrisson présentant une capacité élevée de production de la sérotonine; spécifiquement, Bifidobacterium longum N61 (NITE BP-02214).
PCT/JP2017/011154 2016-03-28 2017-03-21 Bifidobacterium présentant une capacité de promotion de la sécrétion de la sérotonine WO2017169966A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016-064197 2016-03-28
JP2016064197A JP6353478B2 (ja) 2016-03-28 2016-03-28 セロトニン分泌促進能力を有するビフィズス菌

Publications (1)

Publication Number Publication Date
WO2017169966A1 true WO2017169966A1 (fr) 2017-10-05

Family

ID=59964309

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/011154 WO2017169966A1 (fr) 2016-03-28 2017-03-21 Bifidobacterium présentant une capacité de promotion de la sécrétion de la sérotonine

Country Status (2)

Country Link
JP (1) JP6353478B2 (fr)
WO (1) WO2017169966A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022091667A1 (fr) * 2020-10-29 2022-05-05 日清食品ホールディングス株式会社 Bifidobacterium appartenant au genre bifidobacterium pour favoriser la production d'igf -1
CN114525218A (zh) * 2021-12-30 2022-05-24 美益添生物医药(武汉)有限公司 一种长双歧杆菌及其培养方法和其在高产γ-氨基丁酸和5-羟色胺中的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7438709B2 (ja) * 2019-10-02 2024-02-27 日清食品ホールディングス株式会社 認知機能を改善するビフィズス菌

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011517568A (ja) * 2008-04-15 2011-06-16 ネステク ソシエテ アノニム ビフィドバクテリウム・ロンガム及び海馬ｂｄｎｆ発現
JP2013503130A (ja) * 2009-08-25 2013-01-31 ネステク ソシエテ アノニム ビフィドバクテリウム・ロンガム及び機能性ｇｉ障害
WO2013054001A1 (fr) * 2011-10-12 2013-04-18 Gut Guide Oy Élévation et diagnostic du taux de sérotonine
JP2013224287A (ja) * 2012-03-19 2013-10-31 Sapporo Breweries Ltd セロトニン分泌促進剤
JP2015198638A (ja) * 2014-03-31 2015-11-12 サンスター株式会社 ビフィズス菌醗酵方法及び増殖方法
WO2016036615A1 (fr) * 2014-09-03 2016-03-10 California Institute Of Technology Modulation à base microbienne de la biosynthèse de la sérotonine

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011517568A (ja) * 2008-04-15 2011-06-16 ネステク ソシエテ アノニム ビフィドバクテリウム・ロンガム及び海馬ｂｄｎｆ発現
JP2013503130A (ja) * 2009-08-25 2013-01-31 ネステク ソシエテ アノニム ビフィドバクテリウム・ロンガム及び機能性ｇｉ障害
WO2013054001A1 (fr) * 2011-10-12 2013-04-18 Gut Guide Oy Élévation et diagnostic du taux de sérotonine
JP2013224287A (ja) * 2012-03-19 2013-10-31 Sapporo Breweries Ltd セロトニン分泌促進剤
JP2015198638A (ja) * 2014-03-31 2015-11-12 サンスター株式会社 ビフィズス菌醗酵方法及び増殖方法
WO2016036615A1 (fr) * 2014-09-03 2016-03-10 California Institute Of Technology Modulation à base microbienne de la biosynthèse de la sérotonine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HATA T. ET AL.: "Gut microbiota play a critical role in the production of gut luminal serotonin, Psychother", PSYCHOSOM., vol. 84, no. suppl 1, 2015, pages 31, ISSN: 1423-0348 *
REIGSTAD, CHRISTOPHER S. ET AL.: "Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells", FASEB J., vol. 29, no. 4, 2015, pages 1395 - 1403, ISSN: 1530-6860 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022091667A1 (fr) * 2020-10-29 2022-05-05 日清食品ホールディングス株式会社 Bifidobacterium appartenant au genre bifidobacterium pour favoriser la production d'igf -1
CN114525218A (zh) * 2021-12-30 2022-05-24 美益添生物医药(武汉)有限公司 一种长双歧杆菌及其培养方法和其在高产γ-氨基丁酸和5-羟色胺中的应用
CN114525218B (zh) * 2021-12-30 2024-05-07 美益添生物医药(武汉)有限公司 一种长双歧杆菌及其培养方法和其在高产γ-氨基丁酸和5-羟色胺中的应用

Also Published As

Publication number Publication date
JP2017175949A (ja) 2017-10-05
JP6353478B2 (ja) 2018-07-04

Similar Documents

Publication Publication Date Title
CN107075455B (zh) 具有抗炎症及代谢疾病改善功效的植物乳杆菌hac01菌株及其用途
KR102028744B1 (ko) 면역증강 활성, 항산화 활성 및 소화액 내성을 갖는 락토바실러스 플란타룸 hy7717 균주 및 그의 용도
JP6649539B1 (ja) 脂肪蓄積抑制用組成物
KR20160138056A (ko) 부티르산 산생균 및 그 이용
JP6829144B2 (ja) 心理状態改善剤
WO2011050426A4 (fr) Nouvelles souches de bactérie de l'acide lactique et leurs combinaisons pour la fabrication de préparations probiotiques
WO2017169966A1 (fr) Bifidobacterium présentant une capacité de promotion de la sécrétion de la sérotonine
KR20150000372A (ko) 감마아미노부틸산 고생산성 락토바실러스 브레비스 및 그의 용도
KR102251527B1 (ko) 히알루론산 산생 촉진능을 갖는 유산균
TW202002800A (zh) 第iv型過敏用組成物
JPWO2018034203A1 (ja) 新規乳酸菌、新規乳酸菌を有効成分として含有する自然免疫活性化剤、及び新規乳酸菌を含有する飲食品
KR102501957B1 (ko) 인삼으로부터 유래한 신규 락토바실러스 카제이 균주 및 이의 용도
KR20140087518A (ko) Gaba 생산 활성을 갖는 신규 유산균 균주 및 이의 발효 배양물을 함유하는 조성물
EP4209579A1 (fr) Bifidobactérie inhibant l'expression d'un gène de l'atrophie musculaire
KR20030043543A (ko) 김치에서 분리한 내산성 및 내담즙산성이 우수한 신규락토바실러스 플랜타륨 및 이를 함유하는 제품
KR20150118568A (ko) 감마아미노부틸산 고생산성 락토바실러스 브레비스 및 그의 용도
JP2021164435A (ja) ビフィズス菌増殖促進剤
JP6345642B2 (ja) 新規乳酸菌
JP5481702B2 (ja) 免疫賦活作用を有し、且つ胃液耐性を有する新規乳酸菌
WO2021024915A1 (fr) Bifidobacterium ayant une faible activité d'induction de la génération de cytokines inflammatoires et une activité élevée d'induction de la génération de cytokines anti-inflammatoires
JP2022117889A (ja) 酸化ストレス抵抗性付与能（ｉｌ－８抑制能）及び小腸幹細胞遺伝子調節機能を有する乳酸菌
JP2023107155A (ja) 新規乳酸菌及びその利用
JP2020150872A (ja) Ｇｌｐ−１分泌促進能を有する乳酸菌
JPWO2006064791A1 (ja) γ−アミノ酪酸およびγ−アミノ酪酸含有エキスの製造方法
JP2018113892A (ja) 抗炎症性サイトカイン産生誘導能力を有するビフィズス菌

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17774507

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17774507

Country of ref document: EP

Kind code of ref document: A1